Latest News

In this feature, several leaders in the dermatology space were asked how far we have come and where the field is headed in precision medicine.

Boehringer Ingelheim halted EASi-KIDNEY after a DMC found data did not support a meaningful clinical benefit on the trial's primary endpoint.

Wuyts, of University Hospitals Leuven discusses interim FIBRONEER-ON open-label extension data showing nerandomilast's favorable safety profile.

BEACON-HCC offers a new approach to HCC treatment allocation, with key differences from the updated BCLC framework.

Jim Blando, PhD, of Old Dominion University, explains why allergic patients' lung function dropped most 1 year after wildfire smoke exposure.

Diana Isaacs, PharmD, and Natalie Bellini, DNP, discuss Beta Bionics' new insulin patch pump, expected to be commercialized in Q1 2027.

Atacicept also stabilized eGFR and matched placebo on safety, with a full FDA approval filing planned for Q4 2026.

A multi-site qualitative study identifies communication, language, and access barriers standing in the way of removing incorrect penicillin allergy labels.

However, Connect Biopharma's phase 2 Seabreeze STAT Asthma trial's primary treatment-failure end point missed statistical significance.

FDA accepts Cogent's bezuclastinib NDA for advanced systemic mastocytosis, backed by APEX trial data showing durable, high-rate responses.

Oberlin outlines what dermatologists should weigh, beyond APEX's radiographic data, when selecting a biologic for a patient with psoriatic arthritis.

New research links wildfire smoke to lasting respiratory decline and skin flares, months after exposure ends.

David Oberlin, MD, explains why APEX's enriched trial population, not drug mechanism, likely drove its unique radiographic success in psoriatic arthritis.

Wechsler, of National Jewish Health discusses how oral STAT6 degraders like KT-621 could offer a mechanistically distinct treatment option.

Martin Douglass, PhD, and Vanderbilt colleagues found a Bce module that helps C diff evade bacitracin and host iron restriction

Ameluz is now the first FDA-approved photodynamic therapy for a skin cancer, expanding use to superficial basal cell carcinoma (sBCC) in adults.

Phase 3 data show zasocitinib use led to clear or almost clear skin in around 70% of patients by Week 16, setting up an FDA decision in early 2027.

The novel cardiac sarcomere modulator from Edgewise Therapeutics saw substantial improvements in both nonobstructive and obstructive HCM after 12 weeks.

Beta Bionics plans to launch Mint through the pharmacy channel in the first quarter of 2027.

Adam Friedman, MD, breaks down how to say no strategically in dermatology, from delaying an answer to sharing the decision with the requester.

As ragweed and mold drive this year's fall symptom surge, updated GRADE recommendations shift first-line therapy toward combination intranasal treatment.

Stay updated with the latest healthcare breakthroughs, including a new ablation catheter for AFib and progress in the hereditary angioedema pipeline.

Kristina Duffin, MD, dean of the Spencer Fox Eccles School of Medicine, discusses leadership, delegation, and coaching at LEADderm 2026.